Salesforce has given $1 million to College Possible, the national nonprofit promoting college access by students from ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Highlighted text has been updated as of December 20, 2024. The SURMOUNT-1 trial showed that among patients with obesity, once-weekly tirzepatide reduced body weight substantially as compared to ...

The local government department, including the Municipal Corporation Ludhiana, owes the largest share of ₹4.34 crore, ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

President Bola Tinubu has stressed the commitment of his administration to winning the war against insecurity in the country.

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Tirzepatide has been studied in weight management in 2 large, phase 3 studies: SURMOUNT‑1 (n=2,539) in people who did not have diabetes and SURMOUNT‑2 (n=938) in people with type 2 diabetes. Both ...